ATC Group: J01XX11 Tedizolid

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01XX11 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01X Other antibacterials
4 J01XX Other antibacterials
5 J01XX11

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.2 g
PAREN - Parenteral 0.2 g

Active ingredients in J01XX11

Active Ingredient Description
Tedizolid

Tedizolid is an oxazolidinone prodrug. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid is primarily active against Gram-positive bacteria.

Related product monographs

Title Information Source Document Type  
SIVEXTRO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
SIVEXTRO Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Austria (AT)

Brazil (BR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Poland (PL)

Singapore (SG)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.